Ergotamine tartrate
Caffeine / Ergotamine, Ergomar, Migergot (ergotamine tartrate) is a small molecule pharmaceutical. Ergotamine tartrate was first approved as Cafergot on 1982-01-01. It is used to treat cluster headache, migraine disorders, and postpartum hemorrhage in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ergomar
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ergomar | ANDA | 2025-02-25 |
| ergotamine | ANDA | 2013-04-10 |
| ergotamine tartrate and caffeine | ANDA | 2025-03-27 |
| migergot | ANDA | 2022-11-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
| cluster headache | — | D003027 | G44.00 |
| postpartum hemorrhage | — | D006473 | O72 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 3 | 1 | 4 | 2 | 1 | 11 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 3 | 2 | 1 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 2 | 2 | — | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 1 | 1 | 1 | — | 4 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | 2 | 1 | — | 4 |
| Headache | D006261 | — | R51 | 1 | — | 2 | 1 | — | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | — | 2 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | — | — | 1 | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | 1 | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | 2 | — | 3 | — | — | 5 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | 2 | — | 3 | — | — | 5 |
| Peripartum cardiomyopathy | D000099088 | — | O90.3 | — | 1 | 1 | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | 1 | 2 | 1 | — | — | 2 |
| Hyperprolactinemia | D006966 | — | E22.1 | — | — | 2 | — | — | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 1 | — | 1 | 2 |
| Vascular dementia | D015140 | — | F01 | — | 2 | 1 | — | — | 2 |
| Tension-type headache | D018781 | — | G44.2 | — | — | 1 | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | 1 | — | — | — | 6 |
| Syndrome | D013577 | — | — | — | 3 | — | — | — | 3 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | 2 | — | — | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | 1 | — | — | — | 1 |
| Cerebral hemorrhage | D002543 | — | — | 1 | 1 | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 1 | — | — | — | 1 |
| Subdural hematoma | D006408 | — | — | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Anorexia | D000855 | — | R63.0 | 1 | — | — | — | — | 1 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | — | — | — | — | — | — | 1 | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | — | 1 | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 1 | 1 |
| Fibrosis | D005355 | — | — | — | — | — | — | 1 | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 1 | 1 |
| Pituitary neoplasms | D010911 | — | — | — | — | — | — | 1 | 1 |
| Prolactinoma | D015175 | — | — | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ergotamine tartrate |
| INN | ergotamine |
| Description | Ergotamine is a peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. It has a role as a non-narcotic analgesic, a vasoconstrictor agent, a serotonergic agonist, an alpha-adrenergic agonist, a mycotoxin and an oxytocic. It is a conjugate base of an ergotamine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 113-15-5 |
| RxCUI | 4025 |
| ChEMBL ID | CHEMBL2448612 |
| ChEBI ID | — |
| PubChem CID | 8223 |
| DrugBank | DB00696 |
| UNII ID | PR834Q503T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Migergot – Horizon Therapeutics Public
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,065 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ergomar, Ergotamine, Ergotamine tartrate and caffeine, Migergot
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
354 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use